Aclaris Therapeutics, Inc.
ACRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.52 | -0.34 | 0.04 | -0.00 |
| FCF Yield | -4.70% | -5.75% | -7.00% | -18.93% |
| EV / EBITDA | -14.58 | -8.85 | -8.89 | -15.21 |
| Quality | ||||
| ROIC | -11.40% | -11.34% | -10.24% | -52.81% |
| Gross Margin | 83.69% | -4.11% | 65.22% | -0.98% |
| Cash Conversion Ratio | 0.75 | 0.65 | 0.87 | 0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.77% | -18.63% | -16.76% | -14.31% |
| Free Cash Flow Growth | -9.40% | 23.56% | 70.72% | -303.40% |
| Safety | ||||
| Net Debt / EBITDA | 1.60 | 1.51 | 1.72 | 1.76 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,409.18 | -418.14 | -1,114.69 | -42.28 |